








**(A)****(B)****(C)****(D)****(E)****(F)**

**FIGURE S2** The Expression of Tdo2 Is not Required for Colon Cancer Cell Growth or Lung Metastasis. A, Western blot analyses of CT26 cells expressing Tdo2 or the control cells with the indicated antibodies. B, Amounts of kynurenine per cell measured from cell lysate and supernatant of the indicated cell lines. Quantitative measurement was performed by GC-MS/MS. C, qPCR analyses of *Ido1* in the CT26 cells expressing Tdo2 or the control cells. D, Time course of proliferation of CT26 cells expressing Tdo2 measured by Cell Titer-Glo assays. E, The effect of Tdo2 overexpression on the migration of CT26 cells measured by *in vitro* migration assays (upper panel) and Matrigel invasion assays (lower panel). F, Western blot analyses of CT26 cells expressing Tdo2 or the control cells with antibodies for the indicated representative EMT markers (N-Cadherin, Vimentin, and ZEB1).